Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study ; volume:6 ; number:1 ; day:3 ; month:10 ; year:2017 ; pages:1-12 ; date:12.2017
Experimental hematology & oncology ; 6, Heft 1 (3.10.2017), 1-12, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Brown, Jennifer
- Beteiligte Personen und Organisationen
-
Plummer, Ruth
Bauer, Todd M.
Anthony, Stephen
Sarantopoulos, John
Vos, Filip De
White, Mike
Schupp, Marco
Ou, Ying
Vaishampayan, Ulka
SpringerLink (Online service)
- DOI
-
10.1186/s40164-017-0086-1
- URN
-
urn:nbn:de:1111-201711273078
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brown, Jennifer
- Plummer, Ruth
- Bauer, Todd M.
- Anthony, Stephen
- Sarantopoulos, John
- Vos, Filip De
- White, Mike
- Schupp, Marco
- Ou, Ying
- Vaishampayan, Ulka
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures : : a multicenter, open‐label, single‐arm study
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial
Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures : : a multicenter, open‐label, single‐arm study
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial
Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures : : a multicenter, open‐label, single‐arm study
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial
Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial